$MEIP
MEI Pharma, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022010498 Filed on May 23, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $11.41M $9.694M $18.22M
YoY Change -41.1% 19.55% 98.78%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0%
Gross Profit $11.41M $9.694M $18.22M
YoY Change -41.1% 25.83% 110.1%
Gross Profit Margin 100.0% 100.0% 100.0%
Selling, General & Admin $5.771M $8.934M $7.926M
YoY Change -13.01% 43.63% 40.28%
% of Gross Profit 50.56% 92.16% 43.5%
Research & Development $21.84M $22.32M $21.53M
YoY Change 34.03% 24.79% -3.12%
% of Gross Profit 191.34% 230.22% 118.16%
Depreciation & Amortization $85.00K $89.00K $75.00K
YoY Change 30.77% 11.25% 7.14%
% of Gross Profit 0.74% 0.92% 0.41%
Operating Expenses $27.61M $22.32M $21.53M
YoY Change 20.42% 24.79% -3.12%
Operating Profit -$16.20M -$21.56M -$11.24M
YoY Change 356.1% 31.49% -41.49%
Interest Expense $139.0K $12.83M $5.469M
YoY Change -98.04% -239.34% -24.57%
% of Operating Profit
Other Income/Expense, Net -$6.000K $0.00 $0.00
YoY Change -250.0% -100.0% -100.0%
Pretax Income -$16.06M -$8.725M -$12.16M
YoY Change -552.1% -72.13% 6.17%
Income Tax
% Of Pretax Income
Net Earnings -$16.06M -$8.725M -$12.16M
YoY Change -553.12% -65.95% 51.46%
Net Earnings / Revenue -140.73% -90.0% -66.71%
Basic Earnings Per Share -$0.07 -$0.05
Diluted Earnings Per Share -$120.7K -$0.07 -$0.09
COMMON SHARES
Basic Shares Outstanding 133.2M 133.1M 126.7M
Diluted Shares Outstanding 133.1M 128.2M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.3M $169.0M $185.8M
YoY Change -0.11% 2.7% 3.14%
Cash & Equivalents $15.74M $11.11M $12.55M
Short-Term Investments $137.5M $157.9M $173.2M
Other Short-Term Assets $3.830M $5.978M $4.823M
YoY Change 0.55% 32.84% 30.35%
Inventory
Prepaid Expenses
Receivables $10.04M $8.446M $10.15M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $167.1M $183.5M $200.7M
YoY Change 1.4% 3.91% 3.45%
LONG-TERM ASSETS
Property, Plant & Equipment $1.660M $1.439M $1.414M
YoY Change 10.15% -8.29% -13.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $10.71M $10.96M $8.739M
YoY Change 15.44% 14.66% -11.26%
TOTAL ASSETS
Total Short-Term Assets $167.1M $183.5M $200.7M
Total Long-Term Assets $10.71M $10.96M $8.739M
Total Assets $177.8M $194.4M $209.5M
YoY Change 2.15% 4.46% 2.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.918M $8.257M $6.256M
YoY Change 24.59% 48.21% 12.62%
Accrued Expenses $10.82M $10.08M $9.765M
YoY Change 28.78% 29.89% -12.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.44M $23.96M $30.52M
YoY Change 20.94% -28.22% -17.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $101.0M $102.7M $113.5M
YoY Change -3.29% -4.76% 21.47%
Total Long-Term Liabilities $101.0M $102.7M $113.5M
YoY Change -3.29% -4.76% 21.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.44M $23.96M $30.52M
Total Long-Term Liabilities $101.0M $102.7M $113.5M
Total Liabilities $125.4M $126.6M $132.2M
YoY Change 0.64% -10.3% 1.41%
SHAREHOLDERS EQUITY
Retained Earnings -$374.2M -$358.1M -$345.5M
YoY Change 17.05% 11.18% 18.82%
Common Stock $426.6M $425.9M $422.7M
YoY Change 15.55% 16.03% 16.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.41M $67.81M $73.33M
YoY Change
Total Liabilities & Shareholders Equity $177.8M $194.4M $209.5M
YoY Change 2.15% 4.46% 2.74%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$16.06M -$8.725M -$12.16M
YoY Change -553.12% -65.95% 51.46%
Depreciation, Depletion And Amortization $85.00K $89.00K $75.00K
YoY Change 30.77% 11.25% 7.14%
Cash From Operating Activities -$15.50M -$16.96M -$8.566M
YoY Change 37.76% 8.34% -311.51%
INVESTING ACTIVITIES
Capital Expenditures -$306.0K -$114.0K -$51.00K
YoY Change 3725.0% -15.0%
Acquisitions
YoY Change
Other Investing Activities $20.42M $15.27M -$43.32M
YoY Change 104.26% -0.78% 751.04%
Cash From Investing Activities $20.11M $15.16M -$43.37M
YoY Change 101.36% -1.52% 742.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 360.0K 48.87M
YoY Change -70.59% 200.0% 244225.0%
NET CHANGE
Cash From Operating Activities -15.50M -16.96M -8.566M
Cash From Investing Activities 20.11M 15.16M -43.37M
Cash From Financing Activities 20.00K 360.0K 48.87M
Net Change In Cash 4.628M -1.439M -3.070M
YoY Change -486.31% 927.86% 184.26%
FREE CASH FLOW
Cash From Operating Activities -$15.50M -$16.96M -$8.566M
Capital Expenditures -$306.0K -$114.0K -$51.00K
Free Cash Flow -$15.20M -$16.84M -$8.515M
YoY Change 35.14% 7.61% -307.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
CY2022Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2030-01-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2028-03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50484
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0407811
dei Entity Address Address Line1
EntityAddressAddressLine1
11455 El Camino Real
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 us-gaap Liabilities
Liabilities
126623000
CY2021Q2 us-gaap Liabilities
Liabilities
124632000
dei Local Phone Number
LocalPhoneNumber
369-7100
dei Security12b Title
Security12bTitle
Common Stock, $0.00000002 par value
dei Trading Symbol
TradingSymbol
MEIP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
133152045
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11112000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8543000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
157930000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
144883000
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
169042000
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
153426000
CY2022Q1 us-gaap Other Receivables
OtherReceivables
8446000
CY2021Q2 us-gaap Other Receivables
OtherReceivables
7582000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5978000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3809000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
183466000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
164817000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9524000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7774000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1439000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1507000
CY2022Q1 us-gaap Assets
Assets
194429000
CY2021Q2 us-gaap Assets
Assets
174098000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8257000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6355000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10082000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8402000
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4789000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4526000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
828000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
928000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
23956000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20211000
CY2022Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
91920000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
74696000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9211000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7370000
CY2022Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
1536000
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22355000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
133152000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
133152000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112615000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112615000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
425902000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369171000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-358096000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319705000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
67806000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
49466000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
194429000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174098000
CY2022Q1 us-gaap Revenues
Revenues
9694000
CY2021Q1 us-gaap Revenues
Revenues
8109000
us-gaap Revenues
Revenues
29283000
us-gaap Revenues
Revenues
27342000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
405000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1408000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22318000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17884000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63802000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53104000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8934000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6215000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24769000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17780000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
31252000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
24504000
us-gaap Costs And Expenses
CostsAndExpenses
88571000
us-gaap Costs And Expenses
CostsAndExpenses
72292000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21558000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16395000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59288000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44950000
CY2022Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
12773000
CY2021Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-9272000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
20819000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
11035000
CY2022Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
60000
CY2021Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
58000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
78000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
497000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
482000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8725000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25622000
us-gaap Net Income Loss
NetIncomeLoss
-38391000
us-gaap Net Income Loss
NetIncomeLoss
-32936000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8725000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25622000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38391000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32936000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8725000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25622000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-46437000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-53243000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
133056000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112557000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121591000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112505000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133056000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112557000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122482000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113991000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
49466000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17510000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-194000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2539000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
34301000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-12156000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3672000
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48653000
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
212000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2324000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
73334000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8725000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
360000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2837000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
67806000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
77061000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
712000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
64000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3136000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
124000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2942000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
83975000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-8026000
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2609000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
78573000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25622000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
126000
CY2021Q1 meip Stockissuedduringperiodvaluestockwarrantsexercised
Stockissuedduringperiodvaluestockwarrantsexercised
6000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2645000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55728000
us-gaap Profit Loss
ProfitLoss
-38391000
us-gaap Profit Loss
ProfitLoss
-32936000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
20819000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
11035000
us-gaap Share Based Compensation
ShareBasedCompensation
7700000
us-gaap Share Based Compensation
ShareBasedCompensation
8196000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
241000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
215000
meip Non Cash Lease Expense
NonCashLeaseExpense
636000
meip Non Cash Lease Expense
NonCashLeaseExpense
697000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-20420000
meip Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
864000
meip Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
4921000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2169000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1422000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1902000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3134000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1680000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1672000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
17487000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3401000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2569000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2586000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8543000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12331000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11112000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4546000
meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-645000
meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
181000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33242000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20707000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
173000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
700000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
218164000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
325162000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
205117000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
340582000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13220000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14720000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
194000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
572000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
265000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52325000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3200000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3672000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
64000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49031000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9745000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-8000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2386000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
meip Warrants Issued Pursuant To Cashless Exercise
WarrantsIssuedPursuantToCashlessExercise
0
meip Warrants Issued Pursuant To Cashless Exercise
WarrantsIssuedPursuantToCashlessExercise
6000
meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
3
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-358100000
CY2022Q1 meip Cash And Cash Equivalentsshort Term Investments And Common Stock Proceeds Receivable
CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable
169000000.0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Certain reclassifications have been made to the prior year financial statements to conform to the current year financial statement presentation of unbilled receivables and cash flows from financing activities. These changes did not impact previously reported net loss, loss per share, stockholders’ equity, total assets or cash flows.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</span></p>
CY2022Q1 us-gaap Revenues
Revenues
9694000
CY2021Q1 us-gaap Revenues
Revenues
8109000
us-gaap Revenues
Revenues
29283000
us-gaap Revenues
Revenues
27342000
CY2022Q1 us-gaap Revenues
Revenues
9694000
CY2021Q1 us-gaap Revenues
Revenues
8109000
us-gaap Revenues
Revenues
29283000
us-gaap Revenues
Revenues
27342000
meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
29300000
meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
26900000
CY2021Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
0
CY2020Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
83000
meip Receivables Amounts Billed
ReceivablesAmountsBilled
45927000
meip Receivables Amounts Billed
ReceivablesAmountsBilled
18267000
meip Receivables Payments Received
ReceivablesPaymentsReceived
-45927000
meip Receivables Payments Received
ReceivablesPaymentsReceived
-18350000
CY2022Q1 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
0
CY2021Q1 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
0
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7582000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2858000
meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
46791000
meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
22841000
meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-45927000
meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-18267000
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8446000
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7432000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14677000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
19108000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-2513000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-4908000
meip Contract With Customer Liability Milestone Payment Received
ContractWithCustomerLiabilityMilestonePaymentReceived
20000000
meip Contract With Customer Liability Milestone Payment Received
ContractWithCustomerLiabilityMilestonePaymentReceived
366000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32164000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14566000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
96700000
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 meip Potential Milestone Payments Payable
PotentialMilestonePaymentsPayable
20000000.0
CY2022Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2021Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8725000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25622000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38391000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32936000
CY2022Q1 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
0
CY2021Q1 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
0
meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-8046000
meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-20307000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8725000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25622000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-46437000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-53243000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
133056000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112557000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121591000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112505000
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
891000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1486000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133056000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112557000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122482000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113991000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36683000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32651000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26171000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21402000
CY2020Q3 meip Initial Recognition Of Operating Lease Right Of Use Asset
InitialRecognitionOfOperatingLeaseRightOfUseAsset
8700000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8700000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
377000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
377000
us-gaap Operating Lease Cost
OperatingLeaseCost
1130000
us-gaap Operating Lease Cost
OperatingLeaseCost
1130000
CY2022Q1 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
380000
CY2021Q1 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
369000
meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
1139000
meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
615000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2386000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2386000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
380000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1565000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1612000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1168000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1710000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1761000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5450000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13646000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3607000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
10039000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
828000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9211000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
10039000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y9M18D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6694734
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.71
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
157900000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
144900000
meip Unsold Securities Shares And Warrants Under Agreement
UnsoldSecuritiesSharesAndWarrantsUnderAgreement
107500000
CY2022Q1 meip Aggregate Value Of Securities Available Under Agreement
AggregateValueOfSecuritiesAvailableUnderAgreement
123400000
CY2022Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
1500000
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22400000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2837000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2645000
us-gaap Share Based Compensation
ShareBasedCompensation
7700000
us-gaap Share Based Compensation
ShareBasedCompensation
8196000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16668542
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
348547
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2423119
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20591610
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
738
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10115129
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.005
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.688
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.811
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.32
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D

Files In Submission

Name View Source Status
0000950170-22-010498-index-headers.html Edgar Link pending
0000950170-22-010498-index.html Edgar Link pending
0000950170-22-010498.txt Edgar Link pending
0000950170-22-010498-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img103133933_0.jpg Edgar Link pending
meip-20220331.htm Edgar Link pending
meip-20220331.xsd Edgar Link pending
meip-20220331_cal.xml Edgar Link unprocessable
meip-20220331_def.xml Edgar Link unprocessable
meip-20220331_htm.xml Edgar Link completed
meip-20220331_lab.xml Edgar Link unprocessable
meip-20220331_pre.xml Edgar Link unprocessable
meip-ex31_1.htm Edgar Link pending
meip-ex31_2.htm Edgar Link pending
meip-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending